FTY720 Markedly Increases Alloengraftment but Does Not Eliminate Host Anti-Donor T Cells that Cause Graft Rejection on Its Withdrawal  Patricia A. Taylor,

Slides:



Advertisements
Similar presentations
Erik Ames, Salif Harouna, Colin Meyer, Lisbeth A. Welniak, William J
Advertisements

Joseph H. Chewning, Weiwei Zhang, David A. Randolph, C
Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure by Jichun Chen, Karen Lipovsky,
William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D
Combined Effects of Interleukin-7 and Stem Cell Factor Administration on Lymphopoiesis after Murine Bone Marrow Transplantation  Brile Chung, Dullei Min,
Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease  Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,
Stromal-Derived Factor-1α and Interleukin-7 Treatment Improves Homeostatic Proliferation of Naïve CD4+ T Cells after Allogeneic Stem Cell Transplantation 
IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy 
Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A
Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells 
Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine  Weiqing Jing,
Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J
Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation  Jian-ming Li, John Gorechlad,
Volume 25, Issue 9, Pages (September 2017)
William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D
Ex Vivo Rapamycin Generates Th1/Tc1 or Th2/Tc2 Effector T Cells With Enhanced In Vivo Function and Differential Sensitivity to Post-transplant Rapamycin.
LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice  Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.
Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J
Human Progenitor Cells Rapidly Mobilized by AMD3100 Repopulate NOD/SCID Mice with Increased Frequency in Comparison to Cells from the Same Donor Mobilized.
Low c-Kit Expression Level Induced by Stem Cell Factor Does Not Compromise Transplantation of Hematopoietic Stem Cells  Chia-Ling Chen, Katerina Faltusova,
Evelyn C. Nieves, Tomomi Toubai, Daniel C
Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without.
Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J
Volume 3, Issue 5, Pages (November 2014)
Volume 15, Issue 6, Pages (June 2014)
Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens  Hisaki Fujii,
Xinchun Chen, Yi Zeng, Gang Li, Nicolas Larmonier, Michael W
Survival and Function of MiHA Epitope-Specific Host CD8 TM Cells Following Ablative Conditioning and HCT  Alwi M. Shatry, Derry C. Roopenian, Robert B.
The Pentostatin Plus Cyclophosphamide Nonmyeloablative Regimen Induces Durable Host T Cell Functional Deficits and Prevents Murine Marrow Allograft Rejection 
TIM-1 Blockade of the Donor Graft Provides Protection Against Lethal Gvhd  Bettina P. Iliopoulou, PhD, Katie Hsu, MS, Antonio Pierini, MD, Gordon J. Freeman,
Cytotoxic CD8+ T Cells Stimulate Hematopoietic Progenitors by Promoting Cytokine Release from Bone Marrow Mesenchymal Stromal Cells  Christian M. Schürch,
Volume 2, Issue 4, Pages (April 2008)
Andrew R. Cuddihy, Batul T. Suterwala, Shundi Ge, Lisa A
Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice  Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,
Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation  Isabel Barao, Maite.
Christine V. Ichim, Džana D
T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease  Cristina Iclozan, Yu Yu, Chen Liu, Yaming Liang, Tangsheng.
Combined Effects of Interleukin-7 and Stem Cell Factor Administration on Lymphopoiesis after Murine Bone Marrow Transplantation  Brile Chung, Dullei Min,
Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and In Vivo Cytokine.
Volume 25, Issue 9, Pages (September 2017)
T Cell and B Cell Immunity can be Reconstituted with Mismatched Hematopoietic Stem Cell Transplantation Without Alkylator Therapy in Artemis-Deficient.
Clinically Relevant Expansion of Hematopoietic Stem Cells with Conserved Function in a Single-Use, Closed-System Bioprocess  Gerard J. Madlambayan, Ian.
Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease  Isao Tawara,
Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells 
Effector Cells Derived from Host CD8 Memory T Cells Mediate Rapid Resistance against Minor Histocompatibility Antigen-Mismatched Allogeneic Marrow Grafts.
A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.
Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice  Dapeng Wang, Yu Yu, Kelley Haarberg,
A CD4 Domain 1 CC′ Loop Peptide Analogue Enhances Engraftment in a Murine Model of Bone Marrow Transplantation with Sublethal Conditioning  Gabor Varadi,
Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation 
Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.
In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.
B7.2−/− Mature Dendritic Cells Generate T-Helper 2 and Regulatory T Donor Cells in Fetal Mice after In Utero Allogeneic Bone Marrow Transplantation  Swati.
Treatment with GM-CSF Secreting Myeloid Leukemia Cell Vaccine Prior to Autologous- BMT Improves the Survival of Leukemia-Challenged Mice  Jenny Zilberberg,
Recipient B Cells Are Not Required for Graft-Versus-Host Disease Induction  Catherine Matte-Martone, Xiajian Wang, Britt Anderson, Dhanpat Jain, Anthony.
Interleukin 17 Is Not Required for Autoimmune-Mediated Pathologic Damage during Chronic Graft-versus-Host Disease  Xiao Chen, Rupali Das, Richard Komorowski,
FLT3L and Plerixafor Combination Increases Hematopoietic Stem Cell Mobilization and Leads to Improved Transplantation Outcome  Shun He, Jianhong Chu,
Umbilical Cord Blood Xenografts in Immunodeficient Mice Reveal That T Cells Enhance Hematopoietic Engraftment Beyond Overcoming Immune Barriers by Stimulating.
Identification of a T Lineage-Committed Progenitor in Adult Blood
Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells  Christian Scheffold, Yolanda C. Scheffold,
Volume 15, Issue 4, Pages (October 2001)
Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation  Jian-Ming Li, Edmund K.
Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD4+25+ T cells to allow an effective graft-versus-leukemia response 
Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg 
Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation:
All Hematopoietic Stem Cells Engraft in Submyeloablatively Irradiated Mice  Katarina Forgacova, Filipp Savvulidi, Ludek Sefc, Jana Linhartova, Emanuel.
Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic.
Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution  Maria Gendelman, Maryam Yassai,
Induction of Lethal Graft-versus-Host Disease by Anti-CD137 Monoclonal Antibody in Mice Prone to Chronic Graft-versus-Host Disease  Wonyoung Kim, Juyang.
Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice  Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.
Induction of Mixed Chimerism through Transplantation of CD45-Congenic Mobilized Peripheral Blood Stem Cells after Nonmyeloablative Irradiation  Zvonimir.
Presentation transcript:

FTY720 Markedly Increases Alloengraftment but Does Not Eliminate Host Anti-Donor T Cells that Cause Graft Rejection on Its Withdrawal  Patricia A. Taylor, Ryan M. Kelly, Nick D. Bade, Michelle J. Smith, Heather E. Stefanski, Bruce R. Blazar  Biology of Blood and Marrow Transplantation  Volume 18, Issue 9, Pages 1341-1352 (September 2012) DOI: 10.1016/j.bbmt.2012.06.007 Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 FTY results in transient allogeneic donor engraftment in the B cell and myeloid cell lineages, but not in the T cell lineages. B6 mice were irradiated with 5.0 Gy TBI on day −1 and infused with 10 × 106 TCD BALB/c BM on day 0. FTY (3 mg/kg/day) or water was administered orally for 2 weeks (A) or 4 weeks (A-D) from day 0. (A) PBLs were phenotyped for percentage of donor class I+ cells at 5 weeks and 3 months. n = 47-52 mice/group, pool of 4 experiments. *P < .05, FTY versus H20; ˆP < .05, 5 weeks versus 3 months. (B) On day 28 after BMT, PBLs were phenotyped for percentage of donor and host CD19+ B, CD11b+ myeloid, and CD4+ and CD8+ T cells. n = 7-8 mice/group. ˆP < .05, donor H20 versus donor FTY; *P < .05, host H20 versus host FTY. (C) Absolute numbers of donor and host cells of each cell lineage from spleen, peripheral LN pool, and tibias and femurs (BM) harvested 28 days after BMT. n = 6 mice/group. ˆP < .05, donor H20 versus donor FTY; *P < .05, host H20 versus host FTY. (D) Thymi were harvested 28 days after BMT. Shown are the absolute thymocyte numbers of each of the indicated cell populations. n = 8 mice/group. *P < .05, FTY versus H20. Data are mean ± 1 standard error of the mean (SEM). Biology of Blood and Marrow Transplantation 2012 18, 1341-1352DOI: (10.1016/j.bbmt.2012.06.007) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 FTY results in increased stable congenic donor engraftment. B6 CD45.2 mice were irradiated with 1.0 Gy TBI on day −1 and infused with 10 × 106 TCD congenic B6 CD45.1 BM on day 0. FTY or water was administered from day 0 to day 28. PBLs were phenotyped for percentage of donor CD45.1+ cells at 5 weeks and 3 months. N = 26 mice/group, pool of 3 experiments. *P < .05, FTY versus H20. Data are mean ± 1 SEM. Biology of Blood and Marrow Transplantation 2012 18, 1341-1352DOI: (10.1016/j.bbmt.2012.06.007) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 FTY increases donor stem cell homing to the host BM cavity. B6 CD45.2 mice were irradiated with 5.0 Gy TBI on day −1 and infused with 10 × 106 TCD allogeneic BALB/c CD45.1 BM on day 0. To ensure an engrafted control, anti-CD4 and anti-CD8 mAbs were administered on day −2, day 0, and day +4 (designated TCD). FTY was administered on day 0 to day 28. Mice determined to have >92% donor PBLs on day 28 were evaluated for donor CD45.1+lineage−Scal-1+ckit+ stem cell and CD45.1+lineage−Sca-1lockitlo CLP numbers in both femurs and tibias on day 29. (A) A ckit versus Sca-1 contour plot of donor+ lineage− BM cells in 1 representative mouse of 5 in control versus FTY-treated mice. (B) BM, donor stem cell, and donor CLP counts for 5 individual mice per group. The horizontal bar indicates the mean. *P < .05. Biology of Blood and Marrow Transplantation 2012 18, 1341-1352DOI: (10.1016/j.bbmt.2012.06.007) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 FTY blocks T cell progenitor thymic ingress and mature host T cell thymic egress. A separate cohort of mice as described in the legend to Figure 3 were evaluated for total thymocyte and ETP numbers and thymic phenotype on day 30 (A-D) and thymocyte number and phenotype at 3 months after BMT (E). (A) A representative CD4/CD8 plot illustrating that most thymocytes are donor DP in TCD control, indicative of normal thymopoiesis, whereas most thymocytes are host SP in FTY-treated, engrafted mice indicative of blockage of thymopoiesis on day 28 after BMT. (B and C) Numbers of total thymocytes (B) and donor ETPs (C) on day 28 after BMT. The y-axis is a log scale. n = 4-5 mice/group. (D) Total numbers of each thymocyte cell population. The y-axis is a log scale for donor cell populations. n = 4-5 mice/group. (E) Thymocyte numbers at 3 months after BMT, showing that host thymopoiesis was recovered in FTY-treated mice, whereas most thymocytes in TCD controls were of donor origin. n = 5 mice/group. *P < .001; ˆP < .05; NS, not significant (P > .05). Biology of Blood and Marrow Transplantation 2012 18, 1341-1352DOI: (10.1016/j.bbmt.2012.06.007) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Donor CLPs from FTY-treated mice can differentiate into T cell progenitors in in vitro cultures. B6 mice were irradiated with 5.0 Gy TBI on day −1 and infused with 10 × 106 TCD allogeneic BALB/c BM on day 0. To ensure an engrafted BMT control, anti-CD4 and anti-CD8 mAbs were administered on day −2, day 0, and day +4 (designated TCD). FTY was administered on day 0 to day 28. A non-BMT BALB/c control was included. On day 29, BM from mice with >92% donor PBLs was harvested from femurs, tibiae, and spines (pool of 10 mice/group), depleted of host lineage-positive cells, and sorted for donor+lineage−skitloSca-1lo CLP cells. CLPs were cultured on a BM stromal cell line, OP-9DL1, that permits T cell lineage commitment and early T cell differentiation, and phenotyped on the indicated day of culture. Shown is a CD44/CD25 contour plot illustrating maturation from stage DN1 to stage DN4 of T cell development. No significant differences in cell yield are seen. Biology of Blood and Marrow Transplantation 2012 18, 1341-1352DOI: (10.1016/j.bbmt.2012.06.007) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 6 Host SP T cells mediate delayed graft rejection in FTY-treated engrafted mice. (A) PBLs from FTY-treated mice were phenotyped at 4 weeks and 7 weeks after BMT. Shown is the decline in engraftment in each mouse from 4 weeks to 7 weeks. n = 16 mice; P < .001, 4 weeks versus 7 weeks. (B) On day 28 after transplantation, 0.5 × 106 mature B6-type SP thymocytes isolated from FTY-treated allogeneic BMT recipients were adoptively transferred into B6 hosts immediately after lethal irradiation and 1 day before infusion of BALB/c BM. Survival is shown. Mice receiving thymocytes died of graft rejection by day 15, whereas those not receiving thymocytes survived long term. n = 8 mice/group; P < .001. (C) B6 thy1.1 mice were irradiated with 5.0 Gy TBI on day −1 and infused with 10 × 106 TCD allogeneic BALB/c thy1.2 BM on day 0. Mice received FTY daily for 4 weeks. High-level chimeras received either no Ab, anti-NK1.1 mAb to deplete host NK cells, anti-thy1.1 mAb to deplete host T cells, or both anti-NK1.1 and anti-thy1.1 mAbs. Percent donor engraftment at 4 weeks and 3 months is shown. n = 12-18 mice/group; P < .001, 4 weeks versus 3 months for mice receiving no Ab or anti-NK1.1 mAb. Biology of Blood and Marrow Transplantation 2012 18, 1341-1352DOI: (10.1016/j.bbmt.2012.06.007) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 7 FTY stably increases the anti-CD40L mAb-mediated alloengraftment promoting effect in mice receiving low-dose TBI. B6 mice were irradiated with 2.0 Gy (A and C) or 1.0 Gy (B and D) TBI on day −1 and infused with 40 × 106 non-TCD BALB/c BM on day 0. FTY, anti-CD40L, or both was administered for 4 weeks. (A,B) PBLs were phenotyped for percentage of donor cells at 5 weeks and 4 months. (C,D) The percentage of donor and host T cells (CD4+ plus CD8+) in PBLs at 4 months is shown. (A and C) n = 10 mice/group; 1 experiment. (B and D) n = 20 mice/group; pool of 2 experiments. *P < .05, anti-CD40L versus FTY plus anti-CD40L; ˆP = .06, anti-CD40L versus FTY plus anti-CD40L. Data are mean ± 1 SEM. Biology of Blood and Marrow Transplantation 2012 18, 1341-1352DOI: (10.1016/j.bbmt.2012.06.007) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions